NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
16.08
-0.34 (-2.07%)
Jul 17, 2026, 11:05 AM EDT - Market open
NovoCure Employees
NovoCure had 1,605 employees as of December 31, 2025. The number of employees increased by 117 or 7.86% compared to the previous year.
Employees
1,605
Change (1Y)
117
Growth (1Y)
7.86%
Revenue / Employee
$420,196
Profits / Employee
-$107,817
Market Cap
1.86B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,605 | 117 | 7.86% |
| Dec 31, 2024 | 1,488 | 35 | 2.41% |
| Dec 31, 2023 | 1,453 | 133 | 10.08% |
| Dec 31, 2022 | 1,320 | 153 | 13.11% |
| Dec 31, 2021 | 1,167 | 144 | 14.08% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AdaptHealth | 10,900 |
| Enovis | 7,802 |
| UFP Technologies | 4,846 |
| Integra LifeSciences Holdings | 4,427 |
| Neogen | 2,974 |
| Inspire Medical Systems | 1,333 |
| Establishment Labs Holdings | 1,004 |
| Alphatec Holdings | 913 |
NVCR News
- 4 days ago - Novocure resumed with a Neutral at JPMorgan - TheFly
- 16 days ago - Novocure to Report Second Quarter 2026 Financial Results - Business Wire
- 17 days ago - Novocure announces Optune Pax received CE Mark - TheFly
- 17 days ago - Novocure's Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer - Business Wire
- 4 weeks ago - Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR) - PRNewsWire
- 4 weeks ago - Novocure falls -17.0% - TheFly
- 4 weeks ago - Novocure price target lowered to $46 from $48 at H.C. Wainwright - TheFly
- 4 weeks ago - Novocure falls -18.2% - TheFly